|
Market Closed -
NYSE
21:00:02 30/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 142.57 USD | -2.15% |
|
-0.10% | +3.41% |
| 09-30 | Merck's experimental skin disease drug succeeds in mid-stage study | RE |
| 09-30 | Major drugmakers turn to China for licensing deals | RE |
| Market Cap | 273B 241B 228B 206B 388B 26,203B 393B 2,728B 1,050B 13,395B 1,026B 1,004B 42,946B | P/E 2026 * |
20.4x | P/E 2027 * | 17x |
|---|---|---|---|---|---|
| Enterprise Value | 305B 268B 254B 230B 433B 29,217B 438B 3,042B 1,171B 14,936B 1,144B 1,119B 47,886B | EV / Sales 2026 * |
5.28x | EV / Sales 2027 * | 4.91x |
| Free-Float |
91.66% | Yield 2026 * |
3.03% | Yield 2027 * | 3.16% |
| Markets | Quality | ||
|---|---|---|---|
NYSE
| NVS | Delayed | |
CBOE
| NVS | Real-time | |
|
London S.E.
| 0K9E | Delayed | |
|
Mexican S.E.
| NVS N | End-of-day quote | |
|
Tradegate
| NOTA | Real-time | |
|
Deutsche Boerse AG
| NOTA | Delayed | |
|
Börse Stuttgart
| NOTA | Delayed | |
|
Boerse Muenchen
| NOTA | Real-time |
Last Transcript: Novartis AG
| 1 day | -2.15% | ||
| 1 week | -0.10% | ||
| 1 month | -6.24% | ||
| 3 months | -9.03% | ||
| 6 months | -6.66% | ||
| Current year | +3.41% |
| 1 week | 142.56 |  | 147.03 |
| 1 month | 137 | | 164.48 |
| Current year | 135.55 | | 170.46 |
| 1 year | 121.57 | | 170.46 |
| 3 years | 92.19 | | 170.46 |
| 5 years | 74.09 | | 170.46 |
| 10 years | 66.93 | | 170.46 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 31/01/2018 | |
Mukul Mehta
DFI | Director of Finance/CFO | - | 15/03/2026 |
Karen Hale
CMP | Compliance Officer | 58 | 13/04/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Nancy Andrews
BRD | Director/Board Member | 67 | 31/12/2014 |
| Director/Board Member | 69 | 31/12/2015 | |
Ton Büchner
BRD | Director/Board Member | 61 | 31/12/2015 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.15% | -0.10% | - | - | 273B | |
| -2.33% | +0.53% | +51.65% | +115.42% | 1,031B | |
| -1.06% | -1.65% | +42.78% | +69.98% | 638B | |
| -0.65% | -1.32% | +12.98% | +75.49% | 462B | |
| -2.66% | -1.87% | +73.13% | +41.15% | 359B | |
| -1.30% | -5.09% | +22.17% | +39.04% | 335B | |
| -1.77% | -0.54% | +13.75% | +26.72% | 273B | |
| -1.94% | -2.85% | -3.14% | +10.01% | 253B | |
| -0.50% | +3.80% | +49.37% | +56.84% | 228B | |
| -1.47% | -1.53% | +34.28% | +98.89% | 185B | |
| Average | -1.26% | -0.36% | +33.00% | +59.28% | 418.21B | |
| Weighted average by Cap. | -1.30% | -0.35% | +37.40% | +71.06% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 57.67B 50.78B 48.11B 43.44B 81.87B 5,529B 82.93B 576B 222B 2,827B 217B 212B 9,063B | 61.43B 54.09B 51.25B 46.27B 87.2B 5,890B 88.33B 613B 236B 3,011B 231B 226B 9,653B |
| Net income | 14.21B 12.51B 11.86B 10.7B 20.17B 1,362B 20.43B 142B 54.58B 696B 53.36B 52.19B 2,233B | 15.78B 13.9B 13.17B 11.89B 22.41B 1,513B 22.7B 158B 60.63B 774B 59.26B 57.97B 2,480B |
| Net Debt | 31.43B 27.68B 26.22B 23.68B 44.62B 3,014B 45.2B 314B 121B 1,541B 118B 115B 4,940B | 28.26B 24.89B 23.58B 21.29B 40.12B 2,710B 40.64B 282B 109B 1,385B 106B 104B 4,441B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/09/26 | US$142.57 | -2.15% | 3,062,096 |
| 29/09/26 | US$145.71 | -0.80% | 1,598,808 |
| 28/09/26 | US$146.88 | +0.98% | 1,949,456 |
| 25/09/26 | US$145.46 | +1.32% | 1,165,774 |
| 24/09/26 | US$143.57 | +0.60% | 1,887,688 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- NOVN Stock
- NVS Stock
Select your edition
All financial news and data tailored to specific country editions
